These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2737789)

  • 1. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
    Neri B; Cini-Neri G; Bandinelli M; Pacini P; Bartalucci S; Ciapini A
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):217-21. PubMed ID: 2737789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens.
    De Leonardis V; De Scalzi M; Neri B; Bartalucci S; Cinelli P
    Int J Clin Pharmacol Res; 1987; 7(4):307-11. PubMed ID: 3474215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin plus lonidamine: in vivo metabolic effects on the rat heart.
    Neri B; Lottini G; Bandinelli E; Cini-Neri G
    Anticancer Drugs; 1991 Aug; 2(4):401-4. PubMed ID: 1797197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines.
    Cini-Neri G; Neri B
    Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data.
    De Leonardis V; Neri B; Bacalli S; Cinelli P
    Int J Clin Pharmacol Res; 1985; 5(2):137-42. PubMed ID: 3860480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative study of 4'-epi-doxorubicin and doxorubicin cardiotoxicities].
    Suzuki T; Yamamoto H; Iwasaki T; Okamoto S; Iizuka T; Kanda H; Murata K
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2170-6. PubMed ID: 6593004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the comparative distribution and biliary excretion of doxorubicin and 4'-epi-doxorubicin in mice and rats.
    Broggini M; Colombo T; Martini A; Donelli MG
    Cancer Treat Rep; 1980; 64(8-9):897-904. PubMed ID: 6934850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
    Saad SY; Najjar TA; Alashari M
    J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anthracycline-induced cardiotoxicity].
    Petit T
    Bull Cancer; 2004 Nov; 91 Suppl 3():159-65. PubMed ID: 15899623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anthracyclines and mitoxantrone on oxygen uptake and ATP intracellular concentration in rat heart slices.
    Neri B; Cini-Neri G; D'Alterio M
    Biochem Biophys Res Commun; 1984 Dec; 125(3):954-60. PubMed ID: 6596102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical evaluation of 4'-epi-doxorubicin.
    Hurteloup P; Cappelaere P; Armand JP; Mathé G
    Cancer Treat Rep; 1983 Apr; 67(4):337-41. PubMed ID: 6573956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer.
    Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
    Camaggi CM; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F
    Cancer Chemother Pharmacol; 1988; 21(3):221-8. PubMed ID: 3162849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
    Bustová I
    Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Contribution of electron microscopy to the study of anthracycline cardiotoxicity].
    Anjo A; Levi F; Reynes M
    Bull Assoc Anat (Nancy); 1991 Jun; 75(229):7-9. PubMed ID: 1777720
    [No Abstract]   [Full Text] [Related]  

  • 18. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epirubicin (4'-epi-adriamycin].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Jan; 17(1):151-9. PubMed ID: 2404456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.